Boston Scientific Shares Drop 9.03% Amid Trial Update

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: 1 day ago

0mins

BSX-9.02%

Should l Buy BSX?

Source: NASDAQ.COM

Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial for the Watchman heart implant met all safety and efficacy endpoints, yet analysts expressed disappointment, suggesting that growth may not accelerate as anticipated, which could impact investor sentiment negatively.
Surge in Trading Volume: On Monday, trading volume surged to 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating strong investor reaction to the trial update despite the stock's 9.03% decline.
Stock Performance: Boston Scientific closed at $62.92, reflecting a 38% drop over the past year, with a forward P/E ratio of 18, suggesting that the stock may be reasonably priced after significant volatility in its performance.
Market Context: The decline in Boston Scientific's stock aligns with broader pressures in the medical device sector, as peers Medtronic and Stryker also experienced losses, while the S&P 500 and Nasdaq indices fell by 0.39% and 0.73%, respectively.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BSX

Wall Street analysts forecast BSX stock price to rise

22 Analyst Rating

22 Buy

0 Hold

0 Sell

Strong Buy

Current: 62.930

Low

94.00

Averages

108.14

High

132.00

Current: 62.930

Low

94.00

Averages

108.14

High

132.00

Wells Fargo

Overweight

maintain

$65.18

2026-03-30

New

Reason

Wells Fargo

Price Target

$65.18

AI Analysis

2026-03-30

New

maintain

Overweight

Reason

Wells Fargo says that while Boston Scientific's CHAMPION-AF trial met its endpoints, the data is unlikely to accelerate Watchman growth given a slightly higher ischemic stroke rate. Watchman left atrial appendage closure was non-inferior to novel oral anticoagulants on the primary efficacy endpoint, but was numerically worse driven by the rate of stroke being slightly worse for Watchman, the analyst tells investors in a research note. Wells views the CHAMPION-AF as "good, not great." The upside scenario is now unlikely, says the firm, which tweaked Boston Scientific's estimates lower but keeps an Overweight rating on the shares. The stock in early trading is down 6% to $65.18.

Leerink

Mike Kratky

Outperform

maintain

2026-03-30

New

Reason

Leerink

Mike Kratky

Price Target

2026-03-30

New

maintain

Outperform

Reason

Leerink analyst Mike Kratky notes that as expected, Boston Scientific's highly anticipated CHAMPION-AF readout achieved both of its primary safety and efficacy endpoints this weekend at ACC. The firm expects bears to latch onto a few key nuances within the data. However, in-person feedback Leerink received from key opinion leaders and physicians throughout the weekend gave the firm increasing confidence that these results will indeed support an uptick in WATCHMAN procedure volumes. Overall, not the home-run scenario that bulls may have been hoping for following the pronounced recent stretch of volatility, but the CHAMPION data seem likely to serve as a fundamental source of incremental WATCHMAN adoption supporting about 20% growth over the LRP. Leerink expects shares may remain sensitive to several other dynamics on a near-term basis. At Boston's heavily discounted current valuation, the firm remains positive on the stock and reiterates an Outperform rating on the name.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BSX

Unlock Now

About BSX

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Boston Scientific Schedules Q1 2026 Earnings Call

1 day agoPRnewswire

Earnings Call Announcement: Boston Scientific Corporation will host a conference call on April 22, 2026, at 8:00 a.m. ET to discuss its financial results for Q1 2026, providing key business highlights and financial data.
Executive Leadership: The call will be led by Chairman and CEO Mike Mahoney alongside Executive VP and CFO Jon Monson, ensuring that investors receive insights directly from top management regarding the company's financial performance.
Pre-Call Financial Release: The company plans to issue a news release announcing its Q1 financial results prior to the call, aiming to provide timely information that helps investors understand the company's financial health and future outlook.
Live Webcast and Replay: The event will be accessible via a live webcast, with a replay available on Boston Scientific's investor website, ensuring that investors who cannot attend in real-time can still access important information.

Boston Scientific Class Action Reminder for Investors

3 hours agoPRnewswire

Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, resulting in investor losses when the company missed net income expectations.
Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, highlighting its leadership in the field.
Investor Guidance: Investors are advised to carefully select experienced legal counsel rather than firms that merely act as intermediaries, ensuring they receive effective legal support in the class action.

Boston Scientific Class Action Reminder for Investors

4 hours agoGlobenewswire

Class Action Notice: Robbins LLP reminds all investors who purchased Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, that a class action has been filed to protect shareholder rights and seek compensation.
False Information Allegations: The lawsuit alleges that Boston Scientific misled investors during this period by claiming reliable information regarding the company's revenue outlook, while in reality, it faced new competitors that diminished its market share in U.S. electrophysiology.
Significant Stock Price Drop: On February 4, 2026, Boston Scientific announced disappointing fourth quarter and full year 2025 results, causing its stock price to plummet from $91.62 to $75.50, a decline of over 17%, reflecting market concerns about the company's growth potential.
Shareholder Action Guidance: Shareholders can submit their applications by May 4, 2026, to serve as lead plaintiffs in the class action, representing other shareholders in the litigation, and those who choose not to participate can remain absent class members while still being eligible for recovery.

Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions

1 day agoNASDAQ.COM

Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.

Boston Scientific Shares Drop 9.02% Amid Trial Update

1 day agoFool

Significant Stock Decline: Boston Scientific (BSX) closed at $62.92 on Monday, down 9.03%, reflecting investor concerns over new clinical trial information regarding its heart implant, which has weakened market confidence in the company's future growth prospects.
Surge in Trading Volume: The trading volume reached 39.9 million shares, approximately 163% above the three-month average of 15.2 million shares, indicating heightened market attention to the company's news, which may lead to increased short-term price volatility.
Clinical Trial Update: Boston Scientific announced that its CHAMPION-AF trial met all safety and efficacy endpoints for the Watchman FLX heart implant; however, analysts expressed disappointment, suggesting that growth potential may not accelerate as anticipated.
Investor Sentiment Analysis: While analysts maintained outperform ratings on Boston Scientific, the stock has dropped 38% over the past year, and with a current P/E ratio of just 18 times forward earnings, investors should view the company's future growth potential rationally and avoid overreacting to a single trial outcome.